Scholars Central

Conference abstract

Therapeutic targeting of ovarian cancer stem cells

Authors: Daniela Dinulescu

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ovarian cancer is the fifth leading cause of cancer death in women. An exciting hypothesis emerging in cancer biology is that cancer cells with stem cell properties are a major driving force for both tumor development and chemoresistance to therapy based on their propensity to divide indefinitely and survive standard cancer chemotherapy. This could explain the high rate of therapeutic failure and tumor relapse seen in patients. Our research group has recently generated animal models of ovarian cancer that recapitulate the human disease with great accuracy. Our animal models constitute invaluable tools that will help identify, characterize, and define the key roles of ovarian cancer stem cells in tumor metastasis and resistance to chemotherapy. Furthermore, they provide us with unique, relevant systems in which to screen new and exciting therapies specifically targeting ovarian cancer stem cells. Our current investigation focuses on whether ovarian cancer stem cells contribute to platinum chemoresistance and tumor relapse. In addition, we are examining whether key stem cell markers constitute good markers for predicting chemoresistance to platinum and doxorubicin in ovarian cancer. Finally, we plan to test a nanotechnology-based strategy for therapeutic delivery, which will selectively target and sensitize cancer stem cells in a spatiotemporal fashion. This constitutes a novel paradigm in the strategies towards developing effective therapies and a cure for ovarian cancer. It is well established that the chemotherapeutic options used today are of limited value in ovarian cancer patients who relapse. The addition of a front-line therapeutic agent specifically targeting cancer stem cells have the potential to greatly improve the high rate of therapeutic failure and tumor relapse currently seen in ovarian cancer patients and especially platinum resistant or refractory patients worldwide. Our studies aim to reduce cancer mortality rates and improve the quality of life of cancer patients through more efficient and less toxic therapies. Data collected from these key preclinical studies will be instrumental in the design of new human clinical trials for ovarian cancer therapy selectively targeting cancer stem cells.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Stem Cell Research & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Daniela Dinulescu”